Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

NCT07205159 is registered in ClinicalTrials.gov with Forte Biosciences, Inc. as lead sponsor.

NCT NCT07205159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07205159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Lead sponsor
Forte Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 23, 2025
Completion date
March 10, 2027
Enrollment
32 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata